Literature DB >> 14528531

Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Stephen J Jarrett1, Gaye Cunnane, Philip G Conaghan, Sarah J Bingham, Maya H Buch, Mark A Quinn, Paul Emery.   

Abstract

As experience with anti-tumor necrosis factor (TNF-alpha) therapy increases, there has been the expected emergence of reports on uncommon side effects. Large clinical trials identified the development of autoantibodies and postmarketing surveillance has identified problems including tuberculosis. There have been several case reports of drug-induced systemic lupus erythematosus. We describe eight patients with rheumatoid arthritis treated with anti-TNF therapies who developed presumed vasculitis, with different pathophysiologic causes. We discuss the literature and potential causal mechanisms, including disease activity, the role of autoantibodies, and shifts in T cell responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528531

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  44 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade.

Authors:  Julia Kleinert; Matthias Lorenz; Wolfgang Köstler; Walter Hörl; Gere Sunder-Plassmann; Afschin Soleiman
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

3.  Isolated motor conduction block associated with infliximab.

Authors:  A W Michell; A Gaitatzis; J Burge; M M Reilly; R Kapoor; M Koltzenburg
Journal:  J Neurol       Date:  2012-02-18       Impact factor: 4.849

4.  Bilateral diaphragmatic paralysis associated with the use of the tumor necrosis factor-alpha inhibitor adalimumab.

Authors:  Mina Mecheal Benjamin; Alan William Martin; Randall Lee Rosenblatt
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-04

5.  A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.

Authors:  Tae-Hwan Kim; Shin-Seok Lee; Won Park; Yeong Wook Song; Chang-Hee Suh; SooKyoung Kim; Young Nam Lee; Dae Hyun Yoo
Journal:  Clin Drug Investig       Date:  2020-06       Impact factor: 2.859

6.  Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.

Authors:  Maria G Tektonidou; John Serelis; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2006-07-06       Impact factor: 2.980

7.  Tumour necrosis factor alpha blockade and the risk of vasculitis.

Authors:  M De Bandt; B Saint-Marcoux
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

8.  Infliximab-associated neuropathy in RA patients--the importance of considering the diagnosis of mononeuritis multiplex.

Authors:  J Birnbaum
Journal:  Clin Rheumatol       Date:  2006-10-25       Impact factor: 2.980

Review 9.  C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab.

Authors:  Dayavathi Ashok; Shirish Dubey; Ian Tomlinson
Journal:  Clin Rheumatol       Date:  2007-08-22       Impact factor: 2.980

Review 10.  TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.

Authors:  Lauren M Workman; Hasem Habelhah
Journal:  Cell Signal       Date:  2013-04-21       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.